ClinicalTrials.gg
CompletedNCT00570687Updated Oct 16, 2014Results posted

A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes

A Phase 2 interventional study of Technosphere Insulin in Diabetes Mellitus, Type 2, sponsored by Mannkind Corporation. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
34th of 49
30 · median 129
Started
2007
with 6 others
Phase 2
8 of 49
none open now
Registered
25th of 49
by date
Lead sponsor
13 of 49
Mannkind Corporation

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is one of 7 that started in 2007, is one of 8 in phase 2, and was the 25th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The original protocol was a randomized, open-label, 3-way cross-over study with 9 scheduled visits. The visits comprised an initial screening visit, 3 treatment visits for the meal challenge followed by a 2-6-week blood-loss recovery period, an interim safety visit, 3 sequential visits for the glucose clamp, and a final close-out visit.

Protocol Amendment 1 was a randomized, open-label, 2-way cross-over study with 7 visits for each completed subject. The visits comprise an initial screening visit, 2 treatment visits for the meal challenge followed by a 2-6-week blood-loss recovery period, an interim safety visit, 2 sequential visits for the glucose clamp, and a final close-out visit.

For both the original protocol and Protocol Amendment 1, subjects were hospitalized in the clinical unit for all procedures.

Read the detailed description

The original protocol was a randomized, open-label, 3-way cross-over study with 9 scheduled visits. The visits comprised an initial screening visit, 3 treatment visits for the meal challenge followed by a 2-6-week blood-loss recovery period, an interim safety visit, 3 sequential visits for the glucose clamp, and a final close-out visit.

After review of the meal challenge data from the Original Protocol design, it became apparent that the TI Inhalation Powder, insulin lispro, and Exubera doses were not well matched, and resulted in significantly higher insulin exposure following insulin lispro than the two inhaled treatments. All meal challenge visits were completed for the 18 subjects enrolled. However, the glucose clamp visits were discontinued since it was discovered that a direct comparison between the treatments was not possible.

The protocol was amended (Amendment 1) to ensure that the insulin exposures between TI Inhalation Powder and insulin lispro were more suited (increased the TI Inhalation Powder doses and decreased the insulin lispro dose). An Exubera arm was not included in Amendment 1 due to the market removal of this product.

Protocol Amendment 1 was a randomized, open-label, 2-way cross-over study with 7 visits for each completed subject. The visits comprise an initial screening visit, 2 treatment visits for the meal challenge followed by a 2-6-week blood-loss recovery period, an interim safety visit, 2 sequential visits for the glucose clamp, and a final close-out visit.

For both the original protocol and Protocol Amendment 1, subjects were hospitalized in the clinical unit for all procedures.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Inhaled Insulin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving diabetes treatment with insulin for a minimum of 3 months
  • (BMI) of ≤ 34 kg/m2 and ≥ 25 kg/m2
  • ≤ 8.5% based upon results from a central laboratory
  • Non-smoking Males and females ≥ 18 and ≤ 70 years of age
  • A clinical diagnosis of type 2 diabetes mellitus for ≥ 12 months

Exclusion criteria

Exclusion Criteria:

  • Total daily insulin requirement of ≥ 1.2 U/kg body weight
  • Use of Symlin® (pramlintide acetate) and/or Byetta® (exenatide) within the preceding 8 weeks
  • Two or more severe hypoglycemic episodes within 6 months of screening
  • Any hospitalization or emergency room visit due to poor diabetic control within 6 months of Screening
  • Severe complications of diabetes
  • Previous exposure to any inhaled insulin product
  • Currently using an insulin delivery pump
  • Allergy or known to insulin or to any of the drugs to be used in the trial
  • Any pulmonary disease, confirmed by documented history, pulmonary function testing, or radiologic findings
  • Chronic use of systemic
  • Inability to perform PFT maneuvers to meet the recommended American Thoracic Society (ATS) standards of acceptability and repeatability
  • Significant improvement in spirometry following bronchodilation
  • Active respiratory infection
  • Seizure disorder
  • Significant cardiovascular dysfunction and/or history within 3 months of Screening
  • Uncontrolled hypertension with a systolic blood pressure of >160 mm Hg and/or diastolic blood pressure > 95 mm Hg at screening, despite pharmacologic treatment
  • Clinical nephrotic syndrome or renal dysfunction or disease
  • Cancer (other than an excised cutaneous basal cell carcinoma) within the past 5 years or any history of lung neoplasms
  • History of active viral and/or cirrhotic hepatic disease and/or abnormal liver enzymes
  • Active infection eg, (HIV), Hepatitis, or history of severe infection within 30 days of Screening
  • Anemia
  • A previous diagnosis of systemic or collagen vascular disease requiring prior or current treatment with systemic corticosteroids, cytotoxic drugs or penicillamine
  • Any concurrent illness, other than diabetes mellitus not controlled by a stable therapeutic regime
  • Current or previous chemotherapy or radiation therapy that may result in pulmonary toxicity
  • Clinically significant abnormalities on screening laboratory evaluation
  • Female subjects who are pregnant, lactating or planning to become pregnant during the clinical trial period
  • Female subjects of (defined as pre-menopausal and not surgically sterilized or for less than 2 years) not practicing adequate .
  • Current drug or alcohol abuse, or a history of drug or alcohol abuse, that, in the opinion of the PI, would not make the subject a suitable candidate for participation in the clinical trial
  • Exposure to any medications or devices within the previous 30 days prior to trial entry or participation in another clinical trial during this trial
  • Unable and/or unlikely to comprehend and/or follow the trial protocol
  • Concurrent medical or major psychiatric condition which, in the opinion of the PI, makes the subject unsuitable for the clinical trial, or could limit the validity of the and/or impair the subject's ability to participate in the trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    1

    Technosphere Insulin

    Drug: Technosphere Insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Minimum Endogenous Glucose Production (EGP) - Meal Challenge

    Time to minimum EGP post dose

    Time frame: 0-480 minutes

  2. Minimum EGP - Meal Challenge

    Minimum calculated EGP per subject as change from baseline

    Time frame: 0-480 minutes

  3. EGP AOC0-480 - Meal Challenge

    EGP area over the curve from 0 to 480 minutes postdose

    Time frame: 0-480 minutes

07

Results

Posted Oct 16, 2014

Participant flow

This single-center study was conducted at: Profil Institut fur Stoffwechselforschung GmbH Hellersbergstrasse 9 D-41460 Neuss, Germany Principal Investigator: Dr. Klaus Rave First subjects first visit: 20 September 2007 Last subject last visit: 30 January 2009

Meal Challenge 1 (1 Day) - Orig Protocol
Participant flow — Meal Challenge 1 (1 Day) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000333333
Completed0000333333
Not completed0000000000
Washout 1 (7-21 Days) - Orig Protocol
Participant flow — Washout 1 (7-21 Days) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000333333
Completed0000333333
Not completed0000000000
Meal Challenge 2 (1 Day) - Orig Protocol
Participant flow — Meal Challenge 2 (1 Day) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000333333
Completed0000333333
Not completed0000000000
Washout 2 (7-21 Days) - Orig Protocol
Participant flow — Washout 2 (7-21 Days) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000333333
Completed0000333333
Not completed0000000000
Meal Challenge 3 (1 Day) - Orig Protocol
Participant flow — Meal Challenge 3 (1 Day) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000333333
Completed0000333333
Not completed0000000000
Washout 3 (7-21 Days) - Orig Protocol
Participant flow — Washout 3 (7-21 Days) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000333333
Completed0000001010
Not completed0000332323
Withdrew: Sponsor decision0000332323
Clamp 1 (1 Day) - Orig Protocol
Participant flow — Clamp 1 (1 Day) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000001010
Completed0000001010
Not completed0000000000
Washout 4 (7-21 Days) - Orig Protocol
Participant flow — Washout 4 (7-21 Days) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000001010
Completed0000001000
Not completed0000000010
Withdrew: Sponsor decision0000000010
Clamp 2 (1 Day) - Orig Protocol
Participant flow — Clamp 2 (1 Day) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000001000
Completed0000001000
Not completed0000000000
Washout 5 (7-21 Days) - Orig Protocol
Participant flow — Washout 5 (7-21 Days) - Orig Protocol
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started0000001000
Completed0000000000
Not completed0000001000
Withdrew: Sponsor decision0000001000
Meal Challenge 1 (1 Day) - Amendment 1
Participant flow — Meal Challenge 1 (1 Day) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000
Washout 1 (7-21 Days) - Amendment 1
Participant flow — Washout 1 (7-21 Days) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000
Meal Challenge 2 (1 Day) - Amendment 1
Participant flow — Meal Challenge 2 (1 Day) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000
Washout 2 (8 Weeks) - Amendment 1
Participant flow — Washout 2 (8 Weeks) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000
Clamp 1 (1 Day) - Amendment 1
Participant flow — Clamp 1 (1 Day) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000
Washout 3 (7-21 Days) - Amendment 1
Participant flow — Washout 3 (7-21 Days) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000
Clamp 2 (1 Day) - Amendment 1
Participant flow — Clamp 2 (1 Day) - Amendment 1
MilestoneAmendment 1: TI 60 U Then Insulin Lispro 10 UAmendment 1: 10 U Insulin Lispro Then 60 U TIAmendment 1: TI 90 U Then 10 U Insulin LisproAmendment 1: 10 U Insulin Lispro Then 90 U TIOriginal Protocol: TI to Insulin Lispro to ExuberaOriginal Protocol: TI to Exubera to Insulin LisproOriginal Protocol: Exubera to Insulin Lispro to TIOriginal Protocol: Exubera to TI to Insulin LisproOriginal Protocol: Insulin Lispro to TI to ExuberaOriginal Protocol: Insulin Lispro to Exubera to TI
Started4224000000
Completed4224000000
Not completed0000000000

Outcome measures

PrimaryTime to Minimum Endogenous Glucose Production (EGP) - Meal Challenge

Time to minimum EGP post dose

Time frame:
0-480 minutes
Reported as:
Median · Minutes
Time to Minimum Endogenous Glucose Production (EGP) - Meal Challenge
MinutesAmendment 1 - TI Inhalation Powder 90 UAmendment 1 - TI Inhalation Powder 60UAmendment 1 - Insulin Lispro 10 UOriginal Protocol - TI Inhalation Powder 45 UOriginal Protocol - Exubera 4 mgOriginal Protocol - Insulin Lispro 12 U
Time to Minimum Endogenous Glucose Production (EGP) - Meal Challenge75.0 (20 to 80)75.0 (45 to 310)125.0 (80 to 210)60 (30 to 460)160 (80 to 480)130 (50 to 350)
PrimaryMinimum EGP - Meal Challenge

Minimum calculated EGP per subject as change from baseline

Time frame:
0-480 minutes
Reported as:
Mean · µmol/kg/min
Minimum EGP - Meal Challenge
µmol/kg/minAmendment 1 - TI Inhalation Powder 90 UAmendment 1 - TI Inhalation Powder 60UAmendment 1 - Insulin Lispro 10 UOriginal Protocol - TI Inhalation Powder 45 UOriginal Protocol - Exubera 4 mgOriginal Protocol - Insulin Lispro 12 U
Minimum EGP - Meal Challenge-10.29 ± 4.394-6.92 ± 1.584-7.11 ± 2.018-7.59 ± 3.015-7.86 ± 2.962-7.63 ± 2.709
PrimaryEGP AOC0-480 - Meal Challenge

EGP area over the curve from 0 to 480 minutes postdose

Time frame:
0-480 minutes
Reported as:
Mean · µmol/kg
EGP AOC0-480 - Meal Challenge
µmol/kgAmendment 1 - TI Inhalation Powder 90 UAmendment 1 - TI Inhalation Powder 60UAmendment 1 - Insulin Lispro 10 UOriginal Protocol - TI Inhalation Powder 45 UOriginal Protocol - Exubera 4 mgOriginal Protocol - Insulin Lispro 12 U
EGP AOC0-480 - Meal Challenge2272.8 ± 266.22108.7 ± 498.32190.9 ± 674.52129.4 ± 764.42488.3 ± 845.11985.9 ± 623.5

Adverse events

Collected over From the time the informed consent was signed to 30 days after the last study visit or study-related procedure. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amendment 1 -TI Inhalation Powder 90 U—0/6 (0%)5/6 (83.3%)
Amendment 1 - TI Inhalation Powder 60 U—0/6 (0%)4/6 (66.7%)
Amendment 1 - Insulin Lispro 10 U—0/12 (0%)1/12 (8.3%)
Original Protocol - TI Inhalation Powder 45 U—0/18 (0%)5/18 (27.8%)
Original Protocol - Exubera 4 mg—0/18 (0%)1/18 (5.6%)
Original Protocol - Insulin Lispro 12 U—0/18 (0%)7/18 (38.9%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAmendment 1 -TI Inhalation Powder 90 UAmendment 1 - TI Inhalation Powder 60 UAmendment 1 - Insulin Lispro 10 UOriginal Protocol - TI Inhalation Powder 45 UOriginal Protocol - Exubera 4 mgOriginal Protocol - Insulin Lispro 12 U
CoughRespiratory, thoracic and mediastinal disorders5/64/60/121/180/181/18
HypoglycemiaMetabolism and nutrition disorders0/60/60/122/180/184/18
PhlebitisVascular disorders0/61/60/120/180/180/18
NasopharyngitisRespiratory, thoracic and mediastinal disorders1/60/60/120/180/180/18
HeadacheNervous system disorders0/60/61/120/180/181/18
DizzinessNervous system disorders0/60/60/121/180/180/18
TenosynovitisMusculoskeletal and connective tissue disorders0/60/60/121/180/180/18
VomitingGastrointestinal disorders0/60/60/121/180/180/18
Acute sinusitisRespiratory, thoracic and mediastinal disorders0/60/60/120/180/181/18
ErythemaSkin and subcutaneous tissue disorders0/60/60/120/180/181/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Amendment 1Original ProtocolTotal
Mean55.3 ± 7.654.9 ± 6.955.1 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Amendment 1Original ProtocolTotal
Female336
Male91524
08

Study locations

1 site
  • Profil Institute for Metabolic Research
    Neuss, GER, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 5 years 9 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2007
First posted
Dec 11, 2007
Start
Sep 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00570687
Responsible party
Sponsor
First posted
Dec 11, 2007
Start date
Sep 2007
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Oct 16, 2014
Last update
Oct 16, 2014

Study contacts

Klaus Rave, MD
principal investigator · Profil Institute for Metabolic Research
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion